Phase IV study of long term Peg-Intron [peginterferon-alfa-2b] for patients who have failed to respond to Rebetron [peginterferon-alfa-2b/ribavirin/interferon] with advanced fibrosis and cirrhosis secondary to hepatitis C- The Copilot Trial.

Trial Profile

Phase IV study of long term Peg-Intron [peginterferon-alfa-2b] for patients who have failed to respond to Rebetron [peginterferon-alfa-2b/ribavirin/interferon] with advanced fibrosis and cirrhosis secondary to hepatitis C- The Copilot Trial.

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Jul 2017

At a glance

  • Drugs Peginterferon alfa-2b (Primary) ; Colchicine
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Acronyms COPILOT
  • Most Recent Events

    • 17 Apr 2008 Final results will be presented at the European Association for the Study of the Liver 43rd annual meeting in April 2008.
    • 17 Apr 2008 Status changed from in progress to completed, as reported by Schering-Plough.
    • 23 Jun 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top